TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04720911

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: In-person TASCS
Description: In-person clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth TASCS
Description: Telehealth clinician delivery of the intervention, including the Safety Planning Intervention, connection to best-match behavioral health resources, and development of an outpatient treatment plan by a research clinician, facilitated by the TASCS Clinician App.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-administered TASCS
Description: Self-administration of the intervention, including the Safety Planning Intervention, facilitated by the TASCS ED Patient App.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up care
Description: Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up care
Description: Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
Study: NCT06146088

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 Vaccine
Description: Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 Vaccine
Description: Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 Vaccine
Description: Inactivated enterovirus 71 vaccine (human diploid cell) of 3.0EU/0.5mL on Day 0,30
Study: NCT05285384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
Description: SARS-CoV-2 recombinant spike protein (25 μg) with Advax-SM adjuvant (15 mg); a single intramuscular injection into the deltoid muscle of the non-dominant arm
Study: NCT06252532

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Alpha
Description: Rhythmic alpha stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Theta
Description: Rhythmic theta stimulation applied

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Direct cortical stimulation (DCS)
Description: Arrhythmic stimulation paradigm applied

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Direct cortical stimulation (DCS)
Description: Arrhythmic stimulation paradigm applied

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct cortical stimulation (DCS) In-Phase Theta
Description: Rhythmic in-phase theta stimulation applied

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Direct cortical stimulation (DCS) Anti-Phase Theta
Description: Rhythmic anti-phase theta stimulation applied
Study: NCT06092892

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery (BCS or mastectomy) with TAD/SNB
Description: Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant Radiation Therapy
Description: Breast surgery (BCS or mastectomy) with TAD/SNB \& Adjuvant Radiation therapy
Study: NCT06579053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone Tablets (Test)
Description: Take one test tablet each period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone Tablets (Reference)
Description: Take one reference tablet each period
Study: NCT05718843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 425809
Description: BI 425809
Study: NCT03466424

Intervention type: RADIATION
Intervention: preoperative short-course radiotherapy
Description: Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.

Intervention type: RADIATION
Intervention: preoperative short-course radiotherapy
Description: Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.

Intervention type: RADIATION
Intervention: preoperative short-course radiotherapy
Description: Patients will be enrolled into Group 1 to 3 according to the time order of entering the study to receive dose from 6Gy×5F to 8Gy×5F using the traditional 3+3 dose escalation design.
Study: NCT04939545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacain
Description: Intercostal continuous loco-regional ropivacaine (2 mg/ml) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h.~As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Intercostal continuous loco-regional placebo solution (NaCl 0,9%) administration over an elastomeric pump through a surgically placed intercostal catheter (ICC) for a maximum of 72h. As concomitant treatments a standardized anesthesia protocol including intravenous continuous application of propofol and remifentanil is used. Additionally, i.v. metamizol at a dose of 1 g will be administered at the end of surgery as a standard, if not contraindicated.~In a standardized postoperative pain protocol the use of basic oral medication is documented as part of the postoperative follow-up and consists of:~ibuprofen 3 x 400 mg p. o. for 3 days, metamizol 4 x 1 g p. o. for 3 days; if ibuprofen and/or metamizol contraindicated then paracetamol p. o. 3 x 1g for 3 days will be administered; morphine 10 mg p. o. 6 times daily will be given on a patient demand basis.
Study: NCT06481800

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cnotrol group
Description: Routine medical care for RLS and sleep quality in hemodialysis Anemia management, electrolyte balance,Avoiding caffeine and alcohol, establishing a regular sleep schedule leg care,Medicines that increase dopamine in the brain, affecting calcium channels, Opioids , Gabapentin and Pregabali , Benzodiazepines,Regular monitoring of kidney function, blood tests

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Description: Manual lymphatic drainage (MLD) for 20 minutes within after each dialysis session during the first 2 hours the dialysis treatment with routine medical care for dialysis patients
Study: NCT05783583

Intervention type: DEVICE
Intervention: Remote Digital Slit Lamp
Description: Slit Lamp Examination
Study: NCT04975633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bodyport Cardiac Scale
Description: Patients will be instructed to take daily measurements for 90 days. Data will be transmitted to Bodyport and concerning findings (weight gain, change of impedance, elevated heart rate) will be reported back to the medical team. The medical team will either choose to act on the information given or continue to observe trends. Interventions may include titration of therapy, change in therapy, fluid restriction, sodium restriction and lifestyle modification
Study: NCT06503731

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC - prefilled syringe
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Efgartigimod PH20 SC - prefilled syringe
Description: Subcutaneous efgartigimod PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo PH20 SC - prefilled syringe
Description: Subcutaneous placebo PH20 SC given by prefilled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PH20 SC - prefilled syringe
Description: Subcutaneous placebo PH20 SC given by prefilled syringe
Study: NCT06136559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemtabrutinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acalabrutinib
Description: Administered orally
Study: NCT06537232

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greens-based Supplement
Description: Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Greens-based Supplement
Description: Participant will consume one serving of greens-based supplement per day in the morning, for 30 days.
Study: NCT05720039

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic NSM
Description: Robotic-assisted Nipple sparing mastectomy procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open NSM
Description: open nipple-sparing mastectomy procedures
Study: NCT05764161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream 1.5% twice daily (BID) during the continuous and open label treatment period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Ruxolitinib matching vehicle cream 1.5% twice daily (BID) during the vehicle-controlled period.
Study: NCT05061368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil Citrate
Description: Phosphodiesterase Type 5 inhibitor. Known to potentiate nitric oxide mediated vasodilation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05694286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Juvederm Volbella XC hyaluronic acid dermal filler injection
Description: Infraorbital filler injection
Study: NCT06422390

Intervention type: BIOLOGICAL
Intervention: Platelet - Rich Plasma
Description: Platelet - Rich Plasma is a biologic injection created from the patient's own blood. 52cc of the patient's blood is drawn then mixed with 8cc of anticoagulant. The blood mixture will be spun down using a centrifuge that can separate the platelet-rich plasma from the other contents in the blood. Once the centrifuge process is complete the Platelet - Rich Plasma is ready to be used.
Study: NCT06396338

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire is offered to patients who meet the eligibility criteria and who have given their non-objection during the abortion request consultation.~This questionnaire includes questions for screening for anxiety and depressive disorders.
Study: NCT05818137

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sotatercept
Description: SC injection at a starting dose of 0.3 mg/kg with a target dose of 0.7 mg/kg every 21 days plus background PAH therapy.
Study: NCT06363409

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cereal Bar as a recovery food snack
Description: Cereal bar as a recovery snack food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Almond
Description: Almond as a recovery snack food
Study: NCT05583383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: camrelizumab
Description: camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
Study: NCT05713474

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic EMG exam with microEMG
Description: Diagnostic EMG exam with microEMG
Study: NCT06348771

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: monounsaturated fatty acids (MUFA) peanut meal
Description: mixed meal tolerance test and postprandial measurements

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: monounsaturated fatty acids (MUFA) peanut meal
Description: mixed meal tolerance test and postprandial measurements
Study: NCT06285643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV2-GDNF Gene therapy
Description: Bilateral image-guided infusion of AAV2-GDNF into putamen, single dose

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Surgery
Description: Bilateral partial burr/twist holes without dural penetration
Study: NCT06244316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF concentration 1
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 1 solution. 1 drop in each eye three times a day for 4 weeks of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhNGF concentration 2
Description: Recombinant Human Nerve Growth Factor (rhNGF) concentration 2 solution. 1 drop in each eye three times a day for 4 weeks of treatment.
Study: NCT06500013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-designed messages
Description: Messages designed by participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized messages
Description: Messages designed by researchers based on behavioral change theories
Study: NCT06244316

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle (Placebo solution)
Description: Eye drop solution, containing no rhNGF. 1 drop in each eye three times a day for 4 weeks of treatment.
Study: NCT05461339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAB014 Monoclonal Antibody Injection
Description: intravitreal injection at 1.25mg once every 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab Injection [Lucentis]
Description: intravitreal injection at 0.5mg once every 4 weeks
Study: NCT05384431

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Muscle5 and TRIM7
Description: Intake of MUSCLE 5 and TRIM 7 supplements on a daily basis for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mixed exercise
Description: Mixed exercise (aerobic and resistance) three days per week for 12 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Mixed exercise
Description: Mixed exercise (aerobic and resistance) three days per week for 12 weeks
Study: NCT04043598

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.9% Sodium-chloride
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: We will compare two already established treatment protocols: the use of normal saline versus lactated Ringer's for fluid therapy in patients with subarachnoid hemorrhage.
Study: NCT04948333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 40mg BID
Description: One tablet of 40 mg will be taken orally twice a day (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 80mg QD
Description: Two tablets of 40 mg will be taken orally once a day (QD)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001 200mg QD
Description: Five tablets of 40 mg will be taken orally once a day (QD)
Study: NCT06499623

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D
Study: NCT04720911

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up care
Description: Counseling calls and access to the Post-ED Patient and Family App for three months after the index presentation. These resources allow the patient and family to review their safety plan, life plan, and outpatient care plan
Study: NCT06499623

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Albumin, C-Reactive Protein, Cholesterol, Urea, Creatinine, Vitamin D

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedance Analysis
Description: Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioelectrical Impedance Analysis
Description: Total Impedance, Segmental Muscle Analysis, Segmental Fat Analysis, Absolute Muscle Mass Value, Muscle Mass Index, Total Body Fat Percentage, Total Body Water, Phase Angle Measurement

Intervention type: OTHER
Intervention: Nutritional Risk Assessment Questionnaire
Description: Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.

Intervention type: OTHER
Intervention: Nutritional Risk Assessment Questionnaire
Description: Fill in the Questionnaire of the Working Group on Nutritional Care in Oncology and get nutrition risk score. The objective data includes weight loss in 6 months, current BMI and food tolerance, and oncological diagnosis including ongoing anti-cancer treatment.
Study: NCT06193577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Phaseolus Vulgaris L. Dry Extract
Description: Extracts of Phaseolus vulgaris (beans) in association with a balanced diet are known to reduce glycaemia and food intake in rodents and humans thus promoting weight loss.
Study: NCT06470022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Medtronic Evolut FX
Description: TAVI performed with Medtronic Evolut FX
Study: NCT06193577

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo control does not contain active ingredients.
Study: NCT06470022

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Edwards Sapien 3 Ultra Resilia
Description: TAVI performed with Edwards Sapien 3 Ultra Resilia
Study: NCT05281744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia Care Consultation program
Description: The Dementia Care Consultation program uses a telephone-based intervention to provide an in-depth, personalized service for individuals living with ADRD and their care partners. It consists of comprehensive needs assessments, creation and implementation of personalized care plans, monitoring and revising care plans, disease education and support coaching, referrals to community-based organizations for service and support, and access to assistance.
Study: NCT06142136

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with sublingual sprayable microemulsion.
Description: Participants received sublingual sprayable microemulsion of vitamin D3 4000 IU daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with oil droplets
Description: Participants received oil droplets of vitamin D3 4000 IU daily for 30 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D substitution with capsules
Description: Participants received capsules of vitamin D3 4000 IU daily for 30 days.
Study: NCT05671861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trismus Device Prototype
Description: Device is noninvasive and will be inserted between patient's upper and lower teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trismus Device Prototype
Description: Device is noninvasive and will be inserted between patient's upper and lower teeth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Surveys will be administered to participants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: A study-specific, accompanying secure mobile application for users to track progress will be created.
Study: NCT04681339

Intervention type: OTHER
Intervention: Antibiotic treatment
Description: Antibiotic treatment

Intervention type: OTHER
Intervention: No antibiotic treatment
Description: No antibiotic treatment
Study: NCT05238025

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN-RSV vaccine
Description: One injection, suspension for injection, intramuscular use, 0.5mL MVA-BN-RSV virus with a titer of at least 3 x 10E8 infectious units (Inf.U)/0.5mL in a Tris buffer at pH 7.7.
Study: NCT05478980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Night Time Tea
Description: Night-time Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Night Time Tea
Description: Night-time Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Tea
Description: Feel New Tea

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Tea
Description: Feel New Tea
Study: NCT04803214

Intervention type: DEVICE
Group type: OTHER
Intervention: ReActiv8
Description: Market-approved ReActiv8 device implanted